Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			After market 07:14:38 pm
733.5 ^USD	+1.19%		734	+0.07%

Apr. 25	Scholz pledges further support for the pharmaceutical industry	DP
Apr. 25	Scholz promises support for pharma sector in Germany as Merck invests	RE

ELI LILLY AND COMPANY : Jefferies keeps its Buy rating

February 13, 2024 at 04:25 am EST

In his latest research note, analyst Akash Tewari confirms his positive recommendation. The broker Jefferies is keeping its Buy rating. Previously set at USD 814, the target price has been raised to USD 853.

Latest news about Eli Lilly and Company

Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Eli Lilly Acquires Injectables Manufacturing Facility in Wisconsin from Nexus Pharmaceuticals	Apr. 22	MT
Eli Lilly to acquire manufacturing facility from Nexus Pharma	Apr. 22	RE
Eli Lilly: agreement to purchase a Nexus plant in the USA	Apr. 22	CF
Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc.	Apr. 21	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	Apr. 17	MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept	Apr. 17	MT
Trending : Eli Lilly Weight-Loss Drug Works on Sleep Apnea	Apr. 17	DJ
Swiss Stocks Jump as Earnings Bonanza Begins; Luxury Stocks Shine on LVMH Boost	Apr. 17	MT
Wall St slips as dour earnings, chip stocks weigh	Apr. 17	RE
Global markets live: LVMH, ASML, Rio Tinto, Eli Lilly, Tesla...	Apr. 17
Eli Lilly's Weight-loss Drug Improves Sleep Apnea Symptoms in Late-stage Studies	Apr. 17	MT
Sector Update: Health Care Stocks Advance Premarket Wednesday	Apr. 17	MT
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says	Apr. 17	RE
The market is pinning its hopes on earnings reports	Apr. 17
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Eli Lilly's Phase 3 Trials of Tirzepatide to Treat Sleep Apnea Meet Endpoints	Apr. 17	MT
Eli Lilly: positive data in sleep apnea	Apr. 17	CF
Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea	Apr. 17	DJ
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients	Apr. 17	RE

Chart Eli Lilly and Company

Duration

Period

More charts

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

733.5 USD

Average target price

813.3 USD

Spread / Average Target

+10.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B
PFIZER, INC.	-11.77%	144B

Other Pharmaceuticals